In this phase 3 study, researchers sought to determine whether the addition of palbociclib may overcome resistance to endocrine and HER2-directed therapies.

For the new study, researchers recruited 518 patients with advanced triple-positive breast cancer across 109 hospitals in the U.S., Europe, New Zealand and Australia between June 2017 and July 2021.

A new study published in The New England Journal of Medicine found HER2-positive metastatic breast cancer to show that the ...

For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine ...

A literature review by researchers at the Abramson Cancer Center has identified a potential use of the cell cycle inhibitor palbociclib in a variety of cancers. Earlier this year, the FDA approved ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Palbociclib plus ...

Researchers showed the potential of combining 2 precision medicines to overcome treatment resistance. When palbociclib, a breast cancer drug, and crizotinib, a lung cancer drug, were used in ...

A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive, HER2-positive advanced ...

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor–positive, human ...

Credit: Getty Images. Continuing CDK4/6 inhibitor therapy and switching ET after disease progression does not improve progression-free survival vs switching ET alone in HR+, HER2- metastatic breast ...

Significantly longer progression-free survival seen with addition of palbociclib to maintenance anti-HER2 and endocrine therapies.

PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England ...